+

WO2008031357A1 - (3z)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one utile dans la fabrication de médicaments pour traiter les cancers - Google Patents

(3z)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one utile dans la fabrication de médicaments pour traiter les cancers Download PDF

Info

Publication number
WO2008031357A1
WO2008031357A1 PCT/CN2007/070649 CN2007070649W WO2008031357A1 WO 2008031357 A1 WO2008031357 A1 WO 2008031357A1 CN 2007070649 W CN2007070649 W CN 2007070649W WO 2008031357 A1 WO2008031357 A1 WO 2008031357A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
cancer
cancer cells
pyrrol
dihydro
Prior art date
Application number
PCT/CN2007/070649
Other languages
English (en)
Chinese (zh)
Inventor
Long Yu
Haoxing Zhang
Qingyu Lang
Lisha Tang
Jia Li
Original Assignee
Fudan University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fudan University filed Critical Fudan University
Priority to CNA200780018662XA priority Critical patent/CN101448494A/zh
Publication of WO2008031357A1 publication Critical patent/WO2008031357A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Definitions

  • Mitosis is a very important stage in the cell cycle process.
  • the difference between a tumor and a normal cell is infinite hyperplasia, that is, mitosis loses its normal regulation.
  • Most tumors occur due to genomic instability caused by mitosis.
  • Genomic instability is caused by chromosome instability.
  • Chromosomal instability is a characteristic marker of cancer.
  • Abnormal chromosome segregation, central granule replication and segregation can lead to abnormalities in the number of chromosomes per cell, ie aneuploidy, increased chance of heterozygous deletion, loss of tumor suppressor gene or increased number of proto-oncogenes Disrupts cell life metabolism and signaling, increasing the chance of cancer.
  • Kinase plays an important role in the completion of mitosis and cell cycle regulation, and thus has become a research hotspot in molecular biology. Summary of the invention
  • the anticancer drug contains 0.001 to 99% by weight (more preferably 0.01 to 90% by weight;) a compound of the formula I and a pharmaceutically acceptable carrier or excipient.
  • the medicament is also for inhibiting phosphokinase Aurora-B.
  • the anticancer drug is an injection, granule, capsule, solution or tablet.
  • the cancer is selected from the group consisting of liver cancer, colon cancer, gastric cancer, and lung cancer.
  • the tumor cells are selected from the group consisting of liver cancer cells, colon cancer cells, gastric cancer cells, and lung cancer cells.
  • the application amount is from 0.1 mg/kg to 20 mg/kg of body weight per day.
  • the present invention provides the use of a compound having the structure described below for the preparation of an anticancer drug.
  • salts include: salts with alkali or alkaline earth metals such as sodium, potassium, calcium or magnesium, as well as esters, carbamates or other conventional "prodrugs" (when given in this form) In the case of medicine, it can be converted into an active part in the body).
  • the compound s2 can be used for the preparation of an anticancer drug.
  • the present invention detects the action of the compound s2 on tumor cells and cancer cells according to a standard MTS assay, and the results show that the s2 of the present invention is applicable to various tumor cells and cancer cells, such as liver cancer cells, colon cancer cells, gastric cancer cells, lung cancer cells, and the like. , have a killing or inhibition effect.
  • the compound s2 of the present invention has an inhibitory effect on the phosphokinase Aurora-B. This further confirmed that the compound s2 of the present invention has an effect of inhibiting malignant tumors.
  • Aik2 mainly plays a role in the mitosis of cells.
  • Aik2 As a chromosome-associated protein, it is involved in the regulation of the interaction between the centromere and the spindle microtubule. At the metaphase to the late stage, Aik2 migrates from the centromere to the middle zone of the cell, and is distributed at the end of the cell plate and the posterior mitotic bridge. Post-mitotic events are associated with chromosome segregation and cytokinesis. Mutation of Aik2 inhibits the formation of dividing sulcus and leads to the formation of multinucleated cells. Aik2 is located at 17ql3, this region is abnormal in a variety of human cancer cells, and Aik2 is highly expressed in abnormally ploidy colon cancer cell lines. Therefore, researchers are looking for molecules that interact with Aik2 and use them as antitumor drugs.
  • the effective application amount is from 0.1 mg/kg to 20 mg/kg of body weight per day.
  • the antitumor drug prepared may be an injection or a tablet or the like.
  • the present invention can provide different effects when administered (administered;) therapeutically.
  • these materials can be formulated in a non-toxic, inert, andpharmaceutically acceptable aqueous carrier medium, wherein the pH is usually from about 5 to about 8, preferably from about 6 to about 8, although the pH may be The nature of the formulation and the condition to be treated vary.
  • the formulated pharmaceutical compositions can be administered by conventional routes including, but not limited to, intramuscular, intraperitoneal, subcutaneous, intradermal, intratumoral, or topical administration.
  • s2 of the present invention can be used in combination with a suitable pharmaceutically acceptable carrier.
  • suitable pharmaceutically acceptable carrier include, but are not limited to;: saline, buffer, dextrose, water, glycerol, ethanol, and combinations thereof.
  • the pharmaceutical preparation should be matched to the mode of administration.
  • the s2 of the present invention can be prepared in the form of an injection, for example, by a conventional method using physiological saline or an aqueous solution containing glucose and other adjuvants.
  • Pharmaceutical compositions such as tablets and capsules can be prepared by conventional methods.
  • compositions such as injections, solutions, tablets and capsules are preferably prepared under sterile conditions.
  • the amount of active ingredient administered is a therapeutically effective amount, for example from about 1 microgram per kilogram body weight to about 5 milligrams per kilogram body weight per day.
  • the s2 of the present invention can also be used with other therapeutic agents.
  • a therapeutically effective amount of s2 can be administered to a mammal, wherein the therapeutically effective dose is typically at least about 10 micrograms per kilogram of body weight, and in most cases no more than about 80 milligrams per kilogram.
  • the body weight preferably the dose is from about 500 micrograms per kilogram of body weight to about 2 milligrams per kilogram of body weight.
  • specific doses should also consider factors such as the route of administration, the health of the patient, etc., which are within the skill of the skilled physician. Cancer has become the first cause of death, and the substances that kill tumors and cancer cells have become biomedical Research hotspots in the pharmaceutical industry.
  • the s2 of the present invention has a killing or inhibiting effect on various tumor cells and cancer cells; meanwhile, the compound s2 of the present invention has an inhibitory effect on the phosphokinase Aurora-B. This all proves that the compound s2 of the present invention has an effect of inhibiting malignant tumors.
  • the compound s2 of the present invention can be used in combination with a suitable pharmaceutically acceptable carrier to prepare an anticancer drug to inhibit the continued growth of the tumor.
  • the invention is further illustrated below in conjunction with specific embodiments. It is to be understood that the examples are merely illustrative of the invention and are not intended to limit the scope of the invention.
  • the human Aurora-B protein kinase (NCBI accession number NP-004208) was cloned, expressed and purified using the E. coli expression system for high-throughput screening experiments. Using radioisotope techniques, AuroraB phosphorylated substrate MBP (UPSTATE company, CAT # 13-110, lot # 27845 ), the ⁇ - 33 ⁇ solution of [ ⁇ - 33 ⁇ ] - ⁇ the transfer covalently bound in the end thereof, Its Ser is phosphorylated to produce the substrate 33 P-MBP with isotopic labeling. Finally, the activity of the enzyme was detected by counting the scintillation liquid by counting with a liquid scintillation counter, and the inhibition of the activity of the different compounds was observed to initially evaluate the activity of the compound.
  • AuroraB phosphorylated substrate MBP UPSTATE company, CAT # 13-110, lot # 27845
  • the activity of the enzyme was detected by counting the scintillation liquid by counting with a liquid scintillation counter,
  • Seed plate 1000 cells / hole
  • mice liver cancer H22 ascites was diluted 1:4 with physiological saline (cell concentration: about 1-2 ⁇ 10 7 cells/ml), and each mouse was inoculated with 0.2 ml under the right iliac crest, randomly grouped, and set:
  • the drug was administered from the next day after the inoculation, and the administration volume was 0.5 ml/20 g body weight, and continuous intraperitoneal injection was performed for 7 days.
  • the animals were sacrificed by cervical dislocation 10 days after inoculation, and the tumor pieces were dissected and weighed, and the results were judged. The results are shown in Fig. 2. After inoculation of s2, the tumor weight of the mice decreased significantly, and the more s2 inoculated, the more obvious the tumor weight decreased.
  • the pharmaceutical composition in the form of a tablet is prepared by a conventional technique by mixing the following components and then directly compressing the tablet, and the formulation is as follows:

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne l'utilisation de (3Z)-3-(1H-pyrrol-2-ylmethylene)-1,3-dihydro-2H-indol-2-one dans la fabrication de médicaments pour traiter les cancers. Le composé précité permet d'inhiber des cellules cancéreuses du foie, du côlon, des poumons et de l'estomac et de la phosphokinase Aurora-B. Le composé de cette invention peut être formulé sous forme de compositions pharmaceutiques anticancéreuses comportant des excipients pharmaceutiquement acceptables pour supprimer des croissances tumorales continues.
PCT/CN2007/070649 2006-09-07 2007-09-07 (3z)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one utile dans la fabrication de médicaments pour traiter les cancers WO2008031357A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CNA200780018662XA CN101448494A (zh) 2006-09-07 2007-09-07 (3z)-3-(1h-吡咯-2-基亚甲基)-1,3-二氢-2h-吲哚-2-酮在制备抗癌药物中的应用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2006100309148A CN101112371B (zh) 2006-09-07 2006-09-07 化合物s2在制备抗癌药物中的应用
CN200610030914.8 2006-09-07

Publications (1)

Publication Number Publication Date
WO2008031357A1 true WO2008031357A1 (fr) 2008-03-20

Family

ID=39021000

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2007/070649 WO2008031357A1 (fr) 2006-09-07 2007-09-07 (3z)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one utile dans la fabrication de médicaments pour traiter les cancers

Country Status (2)

Country Link
CN (2) CN101112371B (fr)
WO (1) WO2008031357A1 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1365972A (zh) * 2001-01-19 2002-08-28 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途
US6492389B1 (en) * 1998-07-21 2002-12-10 Thomas Jefferson University Small molecule inhibitors of BCL-2 proteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492389B1 (en) * 1998-07-21 2002-12-10 Thomas Jefferson University Small molecule inhibitors of BCL-2 proteins
CN1365972A (zh) * 2001-01-19 2002-08-28 中国人民解放军军事医学科学院毒物药物研究所 吲哚类衍生物及其抗肿瘤用途

Also Published As

Publication number Publication date
CN101112371B (zh) 2010-11-17
CN101112371A (zh) 2008-01-30
CN101448494A (zh) 2009-06-03

Similar Documents

Publication Publication Date Title
CN101107001A (zh) 配合有α,α,α-三氟胸苷和胸苷磷酸化酶抑制剂的抗癌剂
WO2019174571A1 (fr) Composition pharmaceutique et son utilisation dans la préparation d'un médicament pour le traitement d'une résistance multi-médicament de tumeur
CN102552908B (zh) 含青蒿素及青蒿素类衍生物和Bcl-2抑制剂的药物组合物及其应用
TWI295173B (fr)
US8344017B2 (en) Anti-hepatitis C virus agents and anti-HIV agents
EP4424310A1 (fr) Composition pharmaceutique antitumorale comprenant de l'azvudine et d'un inhibiteur de l'egfr/tki
CN101511355B (zh) (2z)-2-(3,4-二羟基亚苄基)-1-苯并呋喃-3(2h)-酮在制备抗癌药物中的应用
CN111053780A (zh) 奥西替尼的药物组合物及其应用
CN107213160B (zh) Nadph在拮抗药物致线粒体毒性中的应用
WO2008031357A1 (fr) (3z)-3-(1h-pyrrol-2-ylmethylene)-1,3-dihydro-2h-indol-2-one utile dans la fabrication de médicaments pour traiter les cancers
WO2008031358A1 (fr) 1,2-dihydroxy-3-methyl-9,10-anthraquinone utile dans la fabrication de médicaments pour traiter les cancers
CN116726022A (zh) 一种egfr抑制剂在制备治疗癌症药物中的用途
CN104434948B (zh) 一种抗胰腺癌的药物组合物及其应用
JP6564952B2 (ja) 腫瘍を予防・治療する医薬およびその用途
US20200061053A1 (en) Pharmaceutical composition and method for acute on chronic liver failure and related liver diseases
CN112933070A (zh) 一种激酶抑制剂及其在制备防治TrkA/B/C激酶异常活化导致疾病药物的用途
CN115252615B (zh) 一种含有防己诺林-7-丙酸酯与parp-1抑制剂的药物组合物
CN115212211B (zh) 双去甲基汉防己甲素双甲酸乙酯与parp-1抑制剂联合治疗肿瘤的用途
CN1655821A (zh) 包括cdk抑制剂和多柔比星的联合
CN101856359A (zh) 一种抗急性髓系白血病的药物组合物
JP4319038B2 (ja) 鉄塩を有効成分として含有する潰瘍性大腸炎治療剤
US20130059812A1 (en) Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil
SG185545A1 (en) Composition for treating chronic hepatitis b, containing clevudine and adefovir dipivoxil
KR20230137321A (ko) 소아암 치료용 의약 조성물
JPH0551566B2 (fr)

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780018662.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07801057

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07801057

Country of ref document: EP

Kind code of ref document: A1

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载